top of page
News, Events and Updates
Search
Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as VP Head of Biostatistics
Mar 9, 2023
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
Feb 7, 2023
Anavex Life Sciences Announces Exceeding of Enrollment Target for ANAVEX®2-73 (blarcamesine)
Feb 2, 2023
Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on February 7, 2023
Jan 31, 2023
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 14, 2022
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 12, 2022
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Dec 2, 2022
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
Dec 1, 2022
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Nov 28, 2022
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
Nov 23, 2022
Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
Nov 8, 2022
5
6
7
8
9
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
